FGF23 and kidney disorder: As outlined earlier, growing evidence indicates that measurement of FGF-23 may serve as a biomarker that provides evidence for a disordered mineral ion homeostasis in CKD patients and predicts abnormal bone mineralization, kidney disease progression, vascular calcifications, and overall mortality.